The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018
Health Services Research · 2024
DOI: 10.1111/1475-6773.14152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Services Research, 2024. Verfasst von Carrie McAdam-Marx und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice & Science, Optum Labs, Visiting Fellow, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Medicare Part C, Insurance, Insulins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert Wood Johnson Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To identify the association between insulin out‐of‐pocket costs (OOPC) and adherence to insulin in Medicare Advantage (MA) patients. Data Sources and Study Setting The study is based on Optum Labs Data Warehouse, a longitudinal, real‐world data asset with de‐identified administrative claims and electronic health record data. Study Design Using descriptive and multivariable logistic regression analyses, we identified the likelihood of patients with diabetes having ≥60 consecutive days between an expected insulin fill date and the actual fill date (refill lapse) by OOPC, categorized by $0, >$0–$20 (reference), >$20–$35, >$35–$50, and > $50 per 30‐day supply. Data Collection/Extraction Methods The study included MA enrollees with type 1 or type 2 diabetes and prescription claims for insulin between 2014 and 2018. Principal Findings Those with average insulin OOPC per 30‐day supply >$35 or $0 were more likely to have an insulin refill lapse versus OOPC of >$0 to $20, with odds ratios ranging 1.18 (95% CI 1.13–1.22) to 1.74 (95% CI 1.66–1.83) depending on OOPC group and diabetes type.
Conclusions
Capping average insulin OOPC at $35 per 30‐day supply may help avoid cost‐related insulin non‐adherence in MA patients; efforts to address non‐cost barriers to medication adherence remain important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice & Science, Optum Labs, Visiting Fellow, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Pharmacotherapy, University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, Utah, USA.
- Optum Labs, Eden Prairie, Minnesota, USA.
ORCID-Profile: Carrie McAdam-Marx
Förderung
- Robert Wood Johnson Foundation
Zitieren
APA
McAdam-Marx, C., Ruiz-Negron, N., Sullivan, J. M., & Tucker, J. M. (2024). The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018. Health Services Research. https://doi.org/10.1111/1475-6773.14152
Vancouver
McAdam-Marx C, Ruiz-Negron N, Sullivan JM, Tucker JM. The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018. Health Services Research. 2024. doi:10.1111/1475-6773.14152
BibTeX
@article{McAdamMarx2024,
author = {McAdam-Marx, Carrie and Ruiz-Negron, Natalia and Sullivan, Jane M and Tucker, Jamie M},
title = {The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018},
journal = {Health Services Research},
year = {2024},
doi = {10.1111/1475-6773.14152}
}
EUVIMED